Drug Approval | December 19, 2022
Sun Pharmaceutical receives warning letter from USFDA for Halol facility
The Halol facility was placed under Import Alert by USFDA.
The Halol facility was placed under Import Alert by USFDA.
The newly built centre will work as the state-of-the-art facility for not just ethical animal studies but spans from basic, applied to regulatory animal research.
Post the sale, Patel family has become the single largest promoter shareholder in the company
Her previous role at Novartis, where she was general manager, data & digital, in global drug development, also included accountability for driving the DCT strategy, programs and platforms
This is a phase two randomized, double-blind, parallel-group, placebo and active-controlled study
The designation recognizes Seeq's expertise in enabling faster insights and better business outcomes for life sciences customers, including Bristol Myers Squibb, with advanced analytics innovations.
This partnership stemmed from a successful customer-supplier relationship spanning several years.
Empagliflozin is a novel sodium glucose co-transporter-2 (SGLT-2) inhibitor, which is useful for improving glycaemic control in adults with type-2 diabetes mellitus.
The company will submit an action plan on the observations and will engage with US FDA for next steps.
LG Chem will receive totaling up to $95.5 million for the China rights
Subscribe To Our Newsletter & Stay Updated
